Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 08 Mar 2018
At a glance
- Drugs JTX 2011 (Primary) ; Nivolumab
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms ICONIC
- Sponsors Jounce Therapeutics
- 08 Mar 2018 According to a Jounce Therapeutics media release, preliminary efficacy data expected in 2H 2018.
- 13 Nov 2017 According to a Jounce Therapeutics media release, preliminary efficacy data expected in 1H 2018.
- 09 Aug 2017 Enrollment has commenced in the phase II Part D portion of this trial according to a Jounce Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History